Details

Autor(en) / Beteiligte

• Schröder, Fritz H
• Hugosson, Jonas
• Roobol, Monique J
• Tammela, Teuvo L.J
• Ciatto, Stefano
• Nelen, Vera
• Kwiatkowski, Maciej
• Lujan, Marcos
• Lilja, Hans
• Zappa, Marco
• Denis, Louis J
• Recker, Franz
• Páez, Alvaro
• Määttänen, Liisa
• Bangma, Chris H
• Aus, Gunnar
• Carlsson, Sigrid
• Villers, Arnauld
• Rebillard, Xavier
• van der Kwast, Theodorus
• Kujala, Paula M
• Blijenberg, Bert G
• Stenman, Ulf-Hakan
• Huber, Andreas
• Taari, Kimmo
• Hakama, Matti
• Moss, Sue M
• de Koning, Harry J
• Auvinen, Anssi

Titel

Prostate-Cancer Mortality at 11 Years of Follow-up

Ist Teil von

• The New England journal of medicine, 2012-03, Vol.366 (11), p.981-990

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2012

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• The European Randomized Study of Screening for Prostate Cancer continues to show a 21% reduction in prostate-cancer mortality in the screening group, after 11 years of follow-up. The number of cancers that would need to be detected to prevent one prostate-cancer death is 37. Screening does not affect all-cause mortality. Screening for prostate cancer has remained controversial, despite results showing a significant reduction in the rate of death from prostate cancer (relative reduction, 20%) among men offered screening for prostate-specific antigen (PSA). 1 The European Randomized Study of Screening for Prostate Cancer (ERSPC) is a multicenter trial initiated in 1991 in the Netherlands and in Belgium, with five more European countries (Sweden, Finland, Italy, Spain, and Switzerland) joining between 1994 and 1998. Recruitment was completed in these centers between 1995 and 2003. Later, France also joined, with enrollment in 2000–2005, but data from the French cohort were not included in the . . .